Balaxi Pharmaceuticals (NSE:BALAXI) Non Operating Income: ₹ Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BALAXI Balaxi Pharmaceuticals Ltd NSE:BALAXI
64 GF Score
Price ₹23.41
GF Value ₹66.16
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Balaxi Pharmaceuticals Non Operating Income?

Balaxi Pharmaceuticals NSE:BALAXI +2.21% 64 Non Operating Income is ₹ Mil as of Jun. 2026. GuruFocus rates NSE:BALAXI with a GF Score™ of 64/100 and a GF Value™ of ₹66.16 (Possible Value Trap). The stock has 4 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Balaxi Pharmaceuticals's Non Operating Income for the three months ended in Jun. 2026 was ₹ Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was ₹ Mil.

Balaxi Pharmaceuticals Non Operating Income Related Terms

Balaxi Pharmaceuticals Non Operating Income Historical Data

* Premium members only.

The historical data trend for Balaxi Pharmaceuticals's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Balaxi Pharmaceuticals Non Operating Income Chart

Balaxi Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Balaxi Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
NSE:BALAXI
64GF Score
Balaxi Pharmaceuticals Ltd NSE:BALAXI
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Balaxi Pharmaceuticals Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of ₹ Mil mean?
Balaxi Pharmaceuticals (NSE:BALAXI) has a Non Operating Income of ₹ Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Balaxi Pharmaceuticals and its competitors.
Is Balaxi Pharmaceuticals' Non Operating Income too high?
Balaxi Pharmaceuticals' current Non Operating Income is ₹ Mil. Overall, Balaxi Pharmaceuticals has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Balaxi Pharmaceuticals' Non Operating Income compare to ZTS?
Balaxi Pharmaceuticals' Non Operating Income of ₹ Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Drug Manufacturers company?
A good Non Operating Income depends on the Drug Manufacturers industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Balaxi Pharmaceuticals and its competitors. Balaxi Pharmaceuticals's current Non Operating Income is ₹ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balaxi Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals (NSE:BALAXI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹66.16, compared to a current price of ₹23.41 — trading 64.6% below its estimated fair value. The current Non Operating Income is ₹ Mil. Balaxi Pharmaceuticals' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Balaxi Pharmaceuticals (NSE:BALAXI), the current Non Operating Income is ₹ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Balaxi Pharmaceuticals (NSE:BALAXI) Overvalued in 2026?

Based on GuruFocus' analysis, Balaxi Pharmaceuticals stock appears to be undervalued. The current stock price of ₹23.41 is trading 64.6% below its estimated GF Value™ of ₹66.16. GuruFocus considers Balaxi Pharmaceuticals to be Possible Value Trap.

Key valuation signals for NSE:BALAXI:

  • Non Operating Income: ₹ Mil
  • GF Value™: ₹66.16 vs. price of ₹23.41 (64.6% below fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the NSE:BALAXI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Balaxi Pharmaceuticals Business Description

Address Phase-III, Road No: 81, Jubilee Hills, Plot No.409, H,No: 8-2-293, MAPS Towers, 3rd Floor, Hyderabad, TG, IND, 500 096
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
64GF Score

Get the complete analysis for NSE:BALAXI

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹23.41
Price
₹66.16
GF Value